DCPrime B.V.
http://www.dcprime.nl/91_welcome.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DCPrime B.V.
SOTIO's Dendritic Cell Vaccines Have Promise In Ovary And Lung Cancer
Interim Phase II data has shown that SOTIO's dendritic cell-based cancer vaccine candidates have efficacy in patients with ovarian cancer and non-small cell lung cancer.
OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
Deals Shaping The Medical Industry, November 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
- Other Names / Subsidiaries
-
- VU University Medical Center (VUmc), DC prime
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice